[225Ac]Ac-LNC1011用于前列腺癌靶向α放射性核素治疗的开发
本研究合成新型PSMA靶向配体LNC1011并用α发射体225Ac标记,在PC3-PIP细胞与荷瘤小鼠中评估放射化学性质、药代动力学、肿瘤摄取及疗效。结果显示[225Ac]Ac-LNC1011放化纯度高、稳定性好,肿瘤摄取与滞留优于PSMA-617,在前列腺癌靶向α治疗中疗效优于[225Ac]Ac-PSMA-617。
要点
- [225Ac]Ac-LNC1011放化纯度>97%,96小时内放化纯度>96%
- LNC1011对PSMA的IC50为16.28 nM,PSMA-617为27.93 nM
- 单次1 µCi与0.5 µCi [225Ac]Ac-LNC1011可完全抑制PC3-PIP肿瘤生长,与0.5 µCi [225Ac]Ac-PSMA-617相似
核心结论
- [225Ac]Ac-LNC1011成功实现高放化纯度与稳定性标记,其肿瘤摄取与滞留较PSMA-617显著改善,在前列腺癌靶向α治疗中疗效显著优于[225Ac]Ac-PSMA-617。
研究设计与样本
- 本研究为放射性药物开发与临床前评估研究,合成基于PSMA结合配体并添加丹磺酰化氨基酸的LNC1011(Dan-PSMA),并以α发射体225Ac进行标记。
- 在PSMA阳性PC3-PIP肿瘤细胞中进行细胞摄取与竞争结合实验,在健康小鼠与PC3-PIP异种移植小鼠模型中经注射[225Ac]Ac-LNC1011进行生物分布研究。
- 开展放射性配体治疗研究与最大耐受剂量(MTD)实验以评估[225Ac]Ac-LNC1011的疗效与安全性。
主要发现
- [225Ac]Ac-LNC1011成功标记,放化纯度>97%,96小时内稳定性好(放化纯度>96%)。
- LNC1011对PSMA的结合亲和力高(IC50=16.28 nM),与PSMA-617(IC50=27.93 nM)相当。
- [225Ac]Ac-LNC1011血液消除半衰期中等(T1/2z=13.4±0.57 h),介于[225Ac]Ac-PSMA-617(T1/2z=5.19±0.12 h)与[225Ac]Ac-PSMA-EB-01(T1/2z=25.18±2.78 h)之间。
- [225Ac]Ac-LNC1011注射后1小时肿瘤摄取为38.28±10.04%ID/g,24小时达峰80.57±3.00%ID/g,并持续至注射后72小时(50.58±5.37%ID/g)。
- 单次1 µCi与0.5 µCi [225Ac]Ac-LNC1011可完全抑制PC3-PIP肿瘤生长,与0.5 µCi [225Ac]Ac-PSMA-617相似;0.1 µCi剂量下[225Ac]Ac-LNC1011观察到部分缓解,给药后20天发现复发,而同条件0.1 µCi [225Ac]Ac-PSMA-617治疗小鼠肿瘤抑制不完全。
关键数值与推荐
- [225Ac]Ac-LNC1011放化纯度>97%,96小时内放化纯度>96%。
- LNC1011的IC50=16.28 nM,PSMA-617的IC50=27.93 nM。
- [225Ac]Ac-LNC1011的T1/2z=13.4±0.57 h,[225Ac]Ac-PSMA-617的T1/2z=5.19±0.12 h,[225Ac]Ac-PSMA-EB-01的T1/2z=25.18±2.78 h。
- [225Ac]Ac-LNC1011注射后1小时肿瘤摄取38.28±10.04%ID/g,24小时峰值80.57±3.00%ID/g,72小时50.58±5.37%ID/g。
- 单次1 µCi与0.5 µCi [225Ac]Ac-LNC1011可完全抑制PC3-PIP肿瘤生长,与0.5 µCi [225Ac]Ac-PSMA-617相似;0.1 µCi [225Ac]Ac-LNC1011观察到部分缓解并于给药后20天复发。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific membrane antigen (PSMA) radioligand therapy (PRLT) has become a promising option for treating metastatic castration-resistant prostate cancer (mCRPC). Radioligands labelled with the 68Ga/177Lu theranostic pair have been most widely used in the clinic for diagnosis and therapy, respectively. This study aims to develop a novel PSMA-targeted radioligand, LNC1011, radiolabeled with alpha-emitter 225Ac, to optimise pharmacokinetic properties and assess its potential for targeted alpha therapy (TAT) in prostate cancer treatment. METHODS: LNC1011 (Dan-PSMA) was synthesised based on a PSMA-binding ligand with the addition of a dansylated amino acid. Systematic radiochemical analyses were conducted to confirm the successful synthesis and radiolabelling of [225Ac]Ac-LNC1011. Cell uptake and competition binding assays were performed in PSMA-positive PC3-PIP tumour cells to evaluate the binding affinity and PSMA targeting specificity. The pharmacokinetics properties and tumour uptake were characterised by biodistribution studies using healthy mice and a PC3-PIP xenograft mouse model injected with [225Ac]Ac-LNC1011. Radioligand therapy studies and maximum tolerated dose (MTD) assays were conducted to systematically evaluate the therapeutic efficacy and the safety of [225Ac]Ac-LNC1011. RESULTS: [225Ac]Ac-LNC1011 was successfully radiolabelled with high radiochemical purity (> 97%) and high stability within 96 h (radiochemical purity > 96%). The high binding affinity of LNC1011 (IC50 = 16.28 nM) to PSMA was comparable to that of PSMA-617 (IC50 = 27.93 nM). Biodistribution studies confirmed that [225Ac]Ac-LNC1011 had moderate blood elimination half-life (T1/2z = 13.4 ± 0.57 h), which was at an optimised level between [225Ac]Ac-PSMA-617 (T1/2z = 5.19 ± 0.12 h) and [225Ac]Ac-PSMA-EB-01 (T1/2z = 25.18 ± 2.78 h). In addition, high tumour uptake of [225Ac]Ac-LNC1011 was identified to be 38.28 ± 10.04%ID/g at 1 h post-injection. The specific uptake gradually increased and peaked at 24 h (80.57 ± 3.00%ID/g) and persisted at a high level up to 72 h post-injection (50.58 ± 5.37%ID/g). Targeted alpha therapy results showed the complete inhibition of PC3-PIP tumour growth after administration of a single dose of 1 µCi and 0.5 µCi of [225Ac]Ac-LNC1011 similar to 0.5 µCi [225Ac]Ac-PSMA-617. At the 0.1 µCi dose level, partial remission was observed for [225Ac]Ac-LNC1011, as recurrence was found 20 days after administration. In contrast, mice treated with 0.1 µCi [225Ac]Ac-PSMA-617 showed incomplete tumour inhibition under the same conditions. CONCLUSION: [225Ac]Ac-LNC1011 was successfully radiolabelled with high radiochemical purity and stability. With significantly improved tumour uptake and retention over PSMA-617, [225Ac]Ac-LNC1011 showed significantly better therapeutic efficacy than [225Ac]Ac-PSMA-617 for targeted alpha therapy of prostate cancer.
引用
- Wen X, Zhao T, Yang H, et al. Development of [225Ac]Ac‑LNC1011 for targeted alpha-radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 39992401. doi:10.1007/s00259-025-07155-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。